|
|
Post by cjm18 on Jun 27, 2021 11:18:23 GMT -5
I'm interested to hear your reasoning for this comment. Could be any of the above but with sales so low like I said in the Vdex thread I have a personal sense of urgency about it. They’re not where they projected they would be as far as revenue. Scripts etc. If they needed money for the trial then there is the answer. Starting the trial in the fall 6-9 months after the 200m raise is not unreasonable. |
|
|
|
Post by golfeveryday on Jun 27, 2021 14:35:42 GMT -5
they have been talking about this Peds trial forever and it is still not starting until the Fall. The big issue before was money. Now they have it. What are they waiting on to start this? Something related to the label maybe? Did they submit for a label update before P3? Waiting on a partner? Or deciding if they want to spend the money? or they are waiting from comments from FDA on label for Tyvaso and want the Black Box earring removed for Afrezza |
|
|
|
Post by sportsrancho on Jun 27, 2021 14:43:15 GMT -5
Or deciding if they want to spend the money? or they are waiting from comments from FDA on label for Tyvaso and want the Black Box earring removed for Afrezza I don’t know, correct me if I’m wrong didn’t Mike say that wasn’t a very big problem? I just think they may be waiting for sales to go so they can justify the expense as a business decision. |
|
|
|
Post by goyocafe on Jun 27, 2021 15:24:32 GMT -5
or they are waiting from comments from FDA on label for Tyvaso and want the Black Box earring removed for Afrezza I don’t know, correct me if I’m wrong didn’t Mike say that wasn’t a very big problem? I just think they may be waiting for sales to go so they can justify the expense as a business decision. Unless he does something different, he’s going to keep waiting. Organic growth of Afrezza sales has been paltry. |
|
|
|
Post by bthomas55ep on Jun 27, 2021 16:54:20 GMT -5
I don’t know, correct me if I’m wrong didn’t Mike say that wasn’t a very big problem? I just think they may be waiting for sales to go so they can justify the expense as a business decision. Unless he does something different, he’s going to keep waiting. Organic growth of Afrezza sales has been paltry. Theoretically, revenue for Tyvasso DPI will begin in the "Fall". Maybe they want to coordinate that revenue stream against the PEDS trial? Just watching. I really don't know much of anything at this point except that "things" feel better. |
|
